NCT05088642已完成1 期
A Phase I Clinical Study Evaluating the Pharmacokinetics and Safety of Hetrombopag Olamine Tablets in Subjects With Mild Hepatic Impairment (Child-Pugh Class A), Moderate Hepatic Impairment (Child-Pugh Class B), and Normal Hepatic Function
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Area under the blood concentration vs time curve (AUC0-inf).
研究概览
简要总结
This is a single-dose, open-label, phase I clinical study evaluating the PK of hetrombopag in subjects with mild hepatic impairment (Child-Pugh Class A), subjects with moderate hepatic impairment (Child-Pugh Class B), as well as age-, weight-, and gender-matched subjects with normal hepatic function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign the informed consent form before the study and fully understand the study content, process, and possible adverse reactions; able to complete the study as required by the clinical study protocol;
- •Subjects (and their partners) are willing to adopt effective contraceptive measures from screening to 6 months after the last study administration. See Appendix 1 for specific contraceptive measures;
- •Aged 18-65 years (inclusive), male or female;
- •Body mass index (BMI = weight (kg)/height2 (m2)): 18-30 kg/m2 (inclusive);
- •For subjects with normal hepatic function: normal or abnormal but not clinically significant laboratory findings (hematology, blood biochemistry, urinalysis, and coagulation function);
- •For subjects with normal hepatic function: no history of severe primary disorders involving major organs, including but not limited to the gastrointestinal, respiratory, renal, hepatic, neural, hematological, endocrine, neoplastic, immunological, psychiatric, or cardiovascular and cerebrovascular disorders.
- •Subjects with hepatic insufficiency must also meet the following inclusion criteria:
- •Have not received medication within 4 weeks before screening, or have received stable medication for at least 4 weeks for hepatic impairment and/or other concurrent diseases requiring long-term treatment;
- •With Child-Pugh Class A or B hepatic insufficiency caused by prior primary liver disorders (except drug-induced liver diseases).
排除标准
- •Average daily consumption of > 5 cigarettes within 3 months before screening;
- •Allergic constitution, or allergy to any component of hetrombopag olamine tablets;
- •Average daily alcohol consumption of > 15 g for females (e.g., 145 mL of wine, 497 mL of beer, or 43 mL of low-alcohol liquor) and > 25 g for males (e.g., 290 mL of wine, 994 mL of beer, or 86 mL of low-alcohol liquor) within 3 months before screening;
- •History of drug abuse within 3 months before screening;
- •Have donated or lost ≥ 400 mL of blood, or have received blood transfusion within 3 months before screening;
- •Have undergone major surgery within 6 months before screening, or with incomplete healing of surgical incision;
- •History of deep vein thrombosis or other thromboembolic events, or clinical symptoms suggesting thrombophilia;
- •Have received TPO receptor agonists (such as eltrombopag and romiplostim) or TPO within 1 month before screening;
- •Have taken Chinese herbal medicines or any drug that affects the PK of hetrombopag within 14 days before study administration (see Appendix 2 for drug-drug interaction evaluation);
- •Hypertension [systolic blood pressure (SBP) ≥ 160 mmHg and/or diastolic blood pressure (DBP) ≥ 100 mmHg, confirmed by a re-measurement];
- •Female subjects who are in lactation or have a positive serum pregnancy test result at screening or during the study;
- •Abnormal and clinically significant 12-lead ECG results (such as tachycardia/bradycardia requiring pharmacological treatment, second- or third-degree atrioventricular block or QTcF interval prolongation (≥ 470 ms for males, ≥ 480 ms for females) (corrected according to Fridericia's formula), or other clinically significant abnormalities assessed by the clinician);
- •Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 calculated using the Modification of Diet in Renal Disease (MDRD) equation;
- •Have malignant tumors or history of malignant tumors within 5 years before screening (except treated non-melanoma skin cancer without sign of recurrence and resected cervical intraepithelial neoplasia);
- •For subjects with normal hepatic function: have participated in any drug or medical device clinical trials within 3 months before screening; for subjects with hepatic insufficiency: have participated in any drug or medical device clinical trials within 1 month before screening;
- •For subjects with normal hepatic function: test positive for hepatitis B surface antigen, hepatitis C antibody or hepatitis C core antigen, HIV antibody, or syphilis antibody in screening;
- •Probably undergo surgery or be hospitalized during the study;
- •Have consumed alcohol (or positive for breath alcohol test), grapefruit/grapefruit juice, or any food or beverage containing methylxanthine (such as coffee, tea, cola, chocolate, and energy drink), have participated in strenuous physical activities, or have other factors that may affect drug absorption, distribution, metabolism, and excretion within 1 day before study administration;
- •Positive for urine drug screening (morphine or marijuana);
- •Subjects judged by the investigator as unsuitable for participating in this study.
- •Additional exclusion criteria for subjects with hepatic insufficiency (those who meet any of the followings are ineligible):
- •History of liver transplant;
- •Liver failure, or liver cirrhosis complicated with hepatic encephalopathy, hepatocellular carcinoma, esophageal and gastric varices hemorrhage, and other complications that, in the opinion of the investigator, make subjects unsuitable for participating in this study;
- •History of any serious diseases, other than primary liver diseases, or history of disorders and/or clinically significant abnormal laboratory findings that, as judged by the investigator, may affect the results of the study, including but not limited to the history of diseases in the circulatory system, endocrine system, nervous system, digestive system, urinary system or blood, immune, mental and metabolic diseases.
- •Positive for HIV antibody screening; a rapid plasma reagin (RPR) test is required for a subject who tests positive for syphilis antibodies, and the subject should be excluded if the RPR result is also positive.
研究组 & 干预措施
Mild hepatic impairment (Child-Pugh Class A)
Experimental
干预措施: Hetrombopag Olamine Tablet (Drug)
Moderate hepatic impairment (Child-Pugh Class B)
Experimental
干预措施: Hetrombopag Olamine Tablet (Drug)
Normal hepatic function
Experimental
干预措施: Hetrombopag Olamine Tablet (Drug)
结局指标
主要结局
Area under the blood concentration vs time curve (AUC0-inf).
时间窗: 0-infinity
Peak plasma concentration (Cmax)
时间窗: 0-120 hours post dose
Area Under the plasma concentration vs time curve (AUC0-120).
时间窗: 0-120 hours post dose
次要结局
- Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)(0-120 hours post dose)
- The number of volunteers with adverse events as a measure of safety and tolerability(up to Day 6)
- Half-life Associated With the Terminal Slope (t½)(0-120 hours post dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body ProductionAlzheimer DiseaseNCT04268953Cerecin12
招募中
4 期
Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of ThrombocytopeniaThrombocytopeniaNCT06562738The Third People's Hospital of Chengdu55
Unknown
1 期
Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal FunctionType2DiabetesNCT05328843PegBio Co., Ltd.24
已完成
1 期
Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic ImpairmentHepatic ImpairmentNCT04993157Novartis Pharmaceuticals54
已完成
1 期
A Phase I Pharmacokinetics Study for KT07 CapsuleHealthy Adult SubjectsPharmacokineticsSafety and TolerabilityNCT05223660Yiling Pharmaceutical Inc.26